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INTRODUCTION
Classical hairy cell leukemia (HCL) is a rare indolent B-cell chronic lymphoproliferative disorder (B-CLPD) characterized by massive splenomegaly, pancytopenia and typical-appearing "hairy cells" infiltrating bone marrow, spleen, liver, and circulating in peripheral blood (PB). These cells show abundant cytoplasm with fine hairy projections and a characteristic reniform nucleus without a nucleolus. Lymphadenopathy is rare. [1] Immunophenotype (IPT) shows characteristic bright coexpression of CD19, CD20, CD22, CD11c and uniformly positive CD25, CD103, and CD123 along with highly prevalent lambda-chain restriction. [2] [3] [4] HCL diagnosis till date relies on the morphological and immunophenotypic features which allow its distinction from other CD5neg, and CD10neg HCL-like splenic lymphomas. Although MAP kinase and activated MEK-ERK pathway was implicated in the pathogenesis of HCL, driver mutations remained unknown. [5] The impact of genome-wide massive parallel sequencing is evident in various hematological malignancies. While mutations in NPM1, FLT3, and CEBPA are already a part of AML classification and risk-stratification, [6] mutations in TET2, SF3B1, ASXL1, DNMT3A, and RUNX1 portend newer prognostic models in MDS. [7] Mutated SF3B1 also showed a strong association with the presence of ring sideroblasts in MDS. [8, 9] Lymphomas such as SMZL, lymphoplasmacytic l y m p h o m a / W a l d e n s t r o m macroglobulinemia, and mantle cell lymphoma have been reported to show frequently mutated NOTCH2, [10] MYD88, [11] and NOTCH1 [12] genes respectively, whereas CLL harbors recurrent mutations in NOTCH1, XPO1, MYD88, and KLHL6. [13] In a landmark paper by Tiacci et al., [14] BRAFV600E mutation (BRAF c. 1799T > A p. Val600Glu) was described as a disease-defining genetic marker present in all cases of HCL and absent in other B-cell neoplasms using whole exome sequencing. The high frequency of this mutation in HCL has been corroborated by few other groups. [15, 16] In view of limited data from Indian subcontinent, the aims of our study were to document the baseline frequency of BRAFV600E in a large series of HCL from our center and to correlate the same with the clinical and pathological findings.
MATERIALS AND METHODS
This is a retrospective study of 46 consecutive patients with HCL seen over a period of 10 years from 2005 to 2014 at our institution. The diagnosis was based on morphological and IPT findings wherever available. Based on the electronic medical records and case files retrieved from the medical record department, clinical information included symptomatology, laboratory data at diagnosis and follow-up, treatment received, and response to treatment. Giemsa-stained bone marrow aspirate (BMA) slides were used for morphological assessment. The BMA sample was subjected to processing, staining with a CLPD antibody panel on a three-color BD FACS Calibur and after 2008 on an 8-color BD FACS Canto II (BD Biosciences, San Jose, CA) up to November 2013. In 2014, the list mode data were acquired in Navios (Beckman Coulter Inc). Clonal B cells were characterized by their expression of CD5, CD10, CD20, CD22, CD11c, CD23, CD38, and surface kappa and lambda light chains. HCL-specific panel including CD25, CD103, and CD123 was added. All antibodies were purchased from BD Biosciences, USA. The intensity of expression was determined as bright, intermediate (int), and dim in comparison to their normal counterparts. H-and E-stained sections of the BM biopsy were also studied wherever available to understand the extent of bone marrow infiltration by leukemic cells.
Genomic DNA was extracted from stained BMA slides using a magnetic bead-based extraction technique that has been validated for use in forensic criminology (ChargeSwitch ® Forensic DNA Purification Kit, Invitrogen™, CA, USA). This DNA was subjected to an amplification refractory mutation system (ARMS)-based polymerase-chain reaction PCR, an allele-specific PCR technique that was modified using fluorescent primers to increase the sensitivity of the assay, [17] followed by capillary electrophoresis on ABI3500 genetic analyzer (Applied Biosystems ® , CA, USA). The PCR was designed to amplify a 200 bp control product, a 144 bp BRAFV600E-specific amplicon and a 97 bp wild-type specific amplicon. As a part of assay validation, we simultaneously tested DNA from fresh PB samples of 10 cases of chronic lymphocytic leukemia (CLL). The gold standard used for the diagnosis of HCL was a combination of immunophenotyping, hairy cell-like morphology, and the demonstration of BRAF V600E by a mutation-specific PCR. At follow-up, recovery of the complete blood count (CBC) parameters was noted as response to treatment. BRAFV600E mutation status was correlated with clinicopathological features and treatment outcomes. 
Statistics

RESULTS
Patient presentation
A total of 46 patients were studied. The median age at diagnosis was 51.5 years (range 26-67 years) with a striking male preponderance (M: F ratio-10.5:1). At presentation, splenomegaly was seen in 73.1% of cases, whereas 30.8% cases and 8.6% cases had hepatomegaly and lymphadenopathy, respectively. Nine patients had infections at onset owing to the immune dysfunction and pancytopenia.
Blood counts
CBC revealed pancytopenia and bicytopenia in 50% and 36.1% of cases, respectively. Thrombocytopenia (82.9%) and anemia (80.6%) were most common, followed by neutropenia (74.3%), monocytopenia (70.6%), and leukopenia (58.3%). Leukocytosis was observed in 4 cases, 2 of which also showed absolute monocytosis.
Morphology
Giemsa-stained BMA smears showed tumor cells with the classical "hairy-cell" morphology in all cases. Mean tumor load in BM was 55% (range: 3%-97%). Trephine biopsies were available in 37/46 cases. The various patterns of bone marrow infiltration were noted; the most common was diffuse interstitial in both mutated and unmutated cases accounting for 25/37 (67.6%) cases. Lymphoid aggregates, sheets of neoplastic cells, and scattered atypical cells were seen in 5/37, 4/37 and 3/37 cases, respectively.
Immunophenotypic analysis
Multicolor flow cytometry data were available in 43 cases. The combined panel of CD20+, CD11c+, CD25+, and CD103+ was observed in 40/43 cases (93%). All but two cases showed uniform bright coexpression of CD20 and CD11c. Aberrant IPT was seen in 13 cases. Single marker deviation such as CD10int (4/13), CD5dim (1/13), CD38bright (1/13), CD23int (2/13), and CD25neg (1/13) was seen in cases with an otherwise typical IPT of HCL. Multiple abnormalities coexisted in four other patients. The IPT of leukemic B cells is summarized in Table 1 and Figure 1 .
Treatment outcomes
All patients were treated with cladribine and demonstrated hematologic remission. The median follow-up was 30 months (range: 0-118 months). Out of the 46 patients, 31 were alive at the last follow-up. Six of them are dead; out of which two had succumbed during treatment. Nine patients were lost to follow-up. Residual disease was assessed in twenty patients by morphology or IPT and found to be present in nine patients (45%) with mutated BRAF. All of these nine patients were alive at last follow-up (duration 6-113 months). Of the five patients with wild-type BRAF, one succumbed, two followed up for 78 and 85 months respectively without relapse while two patients were lost to follow-up.
Molecular testing for BRAFV600E mutation
BRAFV600E mutation was present in 41/46 cases (89.1%), which included the three referred cases which were diagnosed solely on the basis of morphology (as sample for IPT was not available). Three out of the five cases showing wild-type BRAF had a classical HCL IPT of CD11c+/CD25+/CD103+ on flow cytometry analysis whereas the remaining two were CD11c+/CD25-/CD103+. In the CD25-cases, CD123 was consistently positive.
Comparison of BRAFV600E mutated and unmutated cases
The positive and negative predictive values of BRAF mutation for hairy-cell leukemia were both 100% since there were no false-positive or false-negative values. Patients with mutated BRAF tend to present a decade earlier than those with wild-type BRAF (P < 0.05). There was no significant difference between the two groups with respect to CBC findings and prevalence of aberrant phenotypes [ Table 2 ].
DISCUSSION
BRAFV600E mutation has been recently designated as the disease-defining genetic lesion in HCL, [14] whereas it is not seen in HCL-v cases. [14] [15] [16] [17] [18] On the other hand, there are occasional reports of presence of this mutation in other B cell neoplasms, thereby pointing to a potential diagnostic pitfall. [19] [20] [21] For analysis of BRAFV600E mutation, we used an ARMS-PCR technique which was validated for formalin-fixed, paraffin-embedded tissue with a reported sensitivity of 0.5% for the mutant allele. [17] This method proved to be specific in our analysis as the mutation was not detected in consecutive samples of CLL. We documented a prevalence of 89.1% of BRAFV600E mutation in our cohort, which is comparable to 79%, [18] 76%, [22] and 70.6% [16] reported in other studies. However, the detection rate of 100% as published by various groups [14, 15, 23] was not seen in our cohort. DNA in these studies was extracted from either fresh PB, [14] BM biopsy, [15] or fresh PB/BMA and unstained BMA slides [23] selected for tumor load of >30%, >15%, and >10%, respectively. We had five cases of HCL which lacked BRAFV600E mutation. We propose the following explanations. Although PCR is the gold standard for genetic diagnosis of HCL, [24] assay sensitivity in our study could be confounded by DNA integrity in material scraped from archival BMA smears, especially having low-tumor load. Xi et al. [18] described a subset of HCL expressing IgVH4-34 and lacking BRAFV600E mutation. This subset is reported to harbor mutations in other genes such as MAP2K1, ARID1A, and TTN. [25] Recently, novel mutations were described in exon 11 of BRAF gene in HCL negative for V600E (which occurs in exon 15). [26] Immunogenetic analysis was not done in our study.
HCL is reported to have immunophenotypic variations. [4] Lennerz et al. [27] had reported CD5bright HCL having wild-type BRAF and proposed it to be a new variant in HCL lacking BRAFV600E mutation. Our case with CD5dim expression had tested positive for V600E. One case with dim (instead of typical bright) expression of CD20/CD11c showed mutated BRAF and achieved remission on cladribine although later showed residual disease on BMA. BRAF was also mutated in another case with leukocytosis, absence of monocytopenia, and CD25neg (mimicking HCL-v). This patient was in sustained remission at last follow-up (54 months). Clasically, HCL has been identified by the characteristic features of pancytopenia, splenomegaly and monocytopenia whereas HCL-v has shown leukocytosis, absence of monocytopenia, and lack of marrow fibrosis at presentation. [4, 16] CD25 is reported to be typically absent in HCL-v. [2, 22, 28] Thus, BRAFV600E mutation analysis can be useful to substantiate the diagnosis of HCL when clinical or IPT features deviate from typical findings.
Residual disease is known to persist despite hematological remission after standard treatment with cladribine, [29] with prevalence ranging from 13% [30] to 50%. [31] Our data is comparable with these reports. Refractoriness to cladribine has been documented in a subset of HCL with IgVH4-34 expression [32] [33] [34] [35] which was later shown to also lack BRAFV600E mutation. [18] Recent reports highlight the effectiveness of targeted therapy against BRAFV600E mutation in relapse/refractory HCL. [36] [37] [38] Except for age at diagnosis, patients with unmutated BRAF did not differ significantly from those harboring the mutation, at least with respect to laboratory parameters. Our findings have certain implications. One, although BRAFV600E mutation is present in a majority of HCL cases, its absence does not rule out the diagnosis. Two, this mutation is also positive in those HCL cases with features overlapping with HCL-v and thus can aid to establish the diagnosis of former. This distinction is significant as therapy differs in both cases.
CONCLUSION
BRAF mutation analysis does find a place in diagnostic armamentarium of HCL. Select cases can be further investigated for IgVH4-34 expression, novel mutations in BRAF, and mutations in additional genes such as MAP2K1, ARID1A, and TTN. The presence of BRAFV600E mutation paves way for targeted therapy and minimal residual disease monitoring in patients of HCL.
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